- Report
- November 2025
- 150 Pages
Global
From €5406EUR$5,950USD£4,648GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- September 2025
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- September 2026
- 183 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 196 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 198 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- January 2026
- 192 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- January 2026
- 184 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- January 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- August 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- July 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- July 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- February 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more